ATXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Astria Therapeutics Inc (ATXS) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are neutral, options data suggests a lack of strong trading sentiment, and there are no significant positive catalysts or recent news to drive the stock higher. Additionally, the downgrade by Cantor Fitzgerald and the company's negative financial performance, despite some YoY improvement, make it prudent to hold off on investing for now.
The MACD histogram is negative (-0.0615) and contracting, RSI is neutral at 44.865, and moving averages are converging, indicating no clear trend. Support and resistance levels suggest limited immediate upside potential with a pivot at 12.718, resistance at 13.111, and support at 12.324.
NULL. There are no recent news events, significant trading trends, or congress trading data to act as positive catalysts.
Cantor Fitzgerald downgraded the stock to Neutral from Overweight. Additionally, the financials show a net loss of -31.64M in Q3 2025, albeit with some YoY improvement.
In Q3 2025, revenue remained flat at $706,000 YoY. Net income improved by 28.98% YoY but remains negative at -31.64M. EPS improved by 30.95% YoY to -0.55. Gross margin stayed at 100%. Overall, the company is still unprofitable.
Cantor Fitzgerald downgraded the stock to Neutral from Overweight on 2025-11-12, signaling reduced confidence in the stock's performance.
